Latest Articles

Publication Date
Cell map offers insights into endometrial dysfunction in women with PCOS - News-Medical.Net

Cell map offers insights into endometrial dysfunction in women with PCOS News-Medical.Net

Published: March 20, 2025, 5:54 p.m.
High-intensity focused ultrasound with endometrial thermal balloon ablation efficacious and safe for... - Medical Dialogues

High-intensity focused ultrasound with endometrial thermal balloon ablation efficacious and safe for... Medical Dialogues

Published: March 20, 2025, 4:30 p.m.
Endometrial Ablation Market Size to Hit USD 2.15 Bn by 2034 - Precedence Research

Endometrial Ablation Market Size to Hit USD 2.15 Bn by 2034 Precedence Research

Published: March 20, 2025, 1:41 p.m.
Endometrial Cell Atlas in PCOS Could Improve Treatment - Mirage News

Endometrial Cell Atlas in PCOS Could Improve Treatment Mirage News

Published: March 20, 2025, 10:02 a.m.
Glypican3 and serglycin as potential biomarkers involved in the pathogenesis of ovarian endometriosis.

Endometriosis, a non-malignant gynecological disorder characterized by debilitating symptoms, displays several cancer-like characteristics, including metastatic behavior and extracellular matrix (ECM) remodeling. The dynamics of ECM are largely influenced by proteoglycans …

Published: March 20, 2025, midnight
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - The Malaysian Reserve

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy The Malaysian …

Published: March 19, 2025, 10:53 p.m.
AI model detects endometrial cancer at almost 100 per cent accuracy - NT News

AI model detects endometrial cancer at almost 100 per cent accuracy NT News

Published: March 19, 2025, 3:45 p.m.
Canada Approves KEYTRUDA For Advanced Endometrial Cancer - Evrim Ağacı

Canada Approves KEYTRUDA For Advanced Endometrial Cancer Evrim Ağacı

Published: March 19, 2025, 2:55 p.m.
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Weekly Voice

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Weekly Voice

Published: March 19, 2025, 11:20 a.m.
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Yahoo Canada Finance

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Yahoo Canada …

Published: March 19, 2025, 11 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!